Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Amgen Gears Up To Own Worldwide Rights Of Otezla®

By John F. Heerdink, Jr.

Reportedly, Amgen (AMGN) has entered in an agreement with Celgene Corporation (CELG) to acquire the worldwide rights of the only oral, a non-biologic treatment for psoriasis and psoriatic arthritis, Otezla. The acquisition is set to proceed for an amount of $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. Otezla is currently approved in more than 50 markets outside the U.S., including the European Union and Japan with patent exclusivity till at least 2028 in the U.S. Otezla generated sales of $1.6 billion in 2018 and Amgen expects Otezla to grow through global expansion and expects at least low double-digit sales growth on average for the next five years.

“The acquisition of Otezla offers a unique opportunity for Amgen to provide patients an innovative oral therapy for psoriasis and p.soriatic arthritis that fits squarely within our portfolio and complements our Enbrel® and AMGEVITA®brands,” ,”We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions,” stated Robert A. Bradway, chairman and chief executive officer at Amgen.

Dyal Co. LLC to serve as the lead financial advisor and Goldman Sachs & Co as a financial advisor for Amgen. Sullivan & Cromwell LLP to serve as legal advisor to Amgen. Amgen hosted an investor call on the matter on Monday, Aug. 26 at 5 a.m. PT including its Chairman & CEO, Robert A. Bradway, and other senior management members. The archived version of the webcast to be made available for replay for at least 90 days on  Amgen’s website at, under Investors.

If you found this article interesting you should consider learning more about Atossa Genetics (ATOS),  a Seattle-based biotech firm developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Recently Atossa reported Q2 financial results & company update today and the online launch of company CEO Steven Quay’s Tedx UofW Talk, “How to Be Smart When You’re Dense: Preventing Breast Cancer by 2030.” The talk has been posted online at

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.


Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation…..

Read Full Article


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us